ECSP045085A - Stent o injerto vascular recubierto con inhibidores de la proteína tirosina quinasa y método de usar el mismo - Google Patents

Stent o injerto vascular recubierto con inhibidores de la proteína tirosina quinasa y método de usar el mismo

Info

Publication number
ECSP045085A
ECSP045085A EC2004005085A ECSP045085A ECSP045085A EC SP045085 A ECSP045085 A EC SP045085A EC 2004005085 A EC2004005085 A EC 2004005085A EC SP045085 A ECSP045085 A EC SP045085A EC SP045085 A ECSP045085 A EC SP045085A
Authority
EC
Ecuador
Prior art keywords
stent
vascular
inhibitors
same
vascular graft
Prior art date
Application number
EC2004005085A
Other languages
English (en)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of ECSP045085A publication Critical patent/ECSP045085A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/95—Instruments specially adapted for placement or removal of stents or stent-grafts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L31/16—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02—Prostheses implantable into the body
    • A61F2/04—Hollow or tubular parts of organs, e.g. bladders, tracheae, bronchi or bile ducts
    • A61F2/06—Blood vessels
    • A61F2/07—Stent-grafts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/54—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M25/00—Catheters; Hollow probes
    • A61M25/01—Introducing, guiding, advancing, emplacing or holding catheters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

Se divulga un dispositivo, tal como un stent cardiovascular, injerto venoso/arterial autólogo, injerto venoso/arterial prostético, catéter vascular, o desviación vascular, para situar un stent en un vaso sanguíneo, dicho dispositivo está recubierto, o fijado por absorción al mismo, o impregnado, o covalente o iónicamente enlazado al mismo con una cantidad de un inhibidor de la proteína tirosina quinasa. Dicho inhibidor de la proteína tirosina quinasa inhibe la proliferación de las células del músculo liso vascular en un área dentro de un vaso sanguíneo inmediatamente adyacente y/o próxima al dispositivo, mientras que simultáneamente no inhibe la proliferación de las células íntimas vasculares. También se describe un método correspondiente de usar el dispositivo para situar el stent en los vasos sanguíneos.
EC2004005085A 2001-10-25 2004-04-23 Stent o injerto vascular recubierto con inhibidores de la proteína tirosina quinasa y método de usar el mismo ECSP045085A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US34373201P 2001-10-25 2001-10-25

Publications (1)

Publication Number Publication Date
ECSP045085A true ECSP045085A (es) 2004-07-23

Family

ID=23347387

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2004005085A ECSP045085A (es) 2001-10-25 2004-04-23 Stent o injerto vascular recubierto con inhibidores de la proteína tirosina quinasa y método de usar el mismo

Country Status (18)

Country Link
US (1) US20040044405A1 (es)
EP (1) EP1441749A4 (es)
JP (1) JP2006519623A (es)
KR (1) KR20040051618A (es)
CN (1) CN1635858A (es)
BR (1) BR0213497A (es)
CA (1) CA2464093A1 (es)
CO (1) CO5580792A2 (es)
EC (1) ECSP045085A (es)
HU (1) HUP0402036A3 (es)
IL (1) IL161583A0 (es)
MX (1) MXPA04003906A (es)
NO (1) NO20042133L (es)
NZ (1) NZ532593A (es)
PL (1) PL374315A1 (es)
RU (1) RU2004116068A (es)
WO (1) WO2003034938A2 (es)
ZA (1) ZA200403184B (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050261283A1 (en) * 2002-05-13 2005-11-24 Vikas Sukhatme Methods and compositions for the treatment of graft failure
US7238198B2 (en) 2002-06-26 2007-07-03 Cook Incorporated Stent-graft fastening
US20050214343A1 (en) * 2002-07-18 2005-09-29 Patrice Tremble Medical devices comprising a protein-tyrosine kinase inhibitor to inhibit restonosis
US20060240014A1 (en) * 2003-06-03 2006-10-26 Beth Israel Deaconess Medical Center Methods and compounds for the treatment of vascular stenosis
WO2005095641A1 (en) * 2004-03-03 2005-10-13 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with mitogen-activated protein kinase kinase kinase 11 (map3k11)
JP2007537153A (ja) * 2004-03-05 2007-12-20 リジェナークス・バイオファーマスーティカルズ・インコーポレイテッド 細胞外基質蓄積の治療または防止
MX2007001155A (es) * 2004-07-29 2007-08-14 Creabilis Therapeutics Spa Uso de inhibidores de k-252a y de quinasa para la prevencion o el tratamiento de patologias asociadas con hmgb1.
WO2007033152A2 (en) * 2005-09-12 2007-03-22 Conor Medsystems, Inc. Composition, system and method for modulating release kinetics in implantable drug delivery devices by modifying drug solubility
US20070196428A1 (en) 2006-02-17 2007-08-23 Thierry Glauser Nitric oxide generating medical devices
JP5110559B2 (ja) * 2006-11-24 2012-12-26 学校法人近畿大学 被覆ステント
TW200940527A (en) 2007-12-07 2009-10-01 Vertex Pharma Solid forms of 1-ethyl-3-(5-(5-fluoropyridin-3-yl)-7-(pyrimidin-2-yl)-1H-benzo[d]imidazol-2-yl)urea
US9126025B2 (en) * 2008-05-01 2015-09-08 Bayer Intellectual Property Gmbh Method of coating a folded catheter balloon
EP2396303A2 (en) 2009-02-13 2011-12-21 Vertex Pharmaceuticals Incorporated Solid forms of 2-(2, 4-difluorophenyl)-6-(1-(2,6-difluorophenyl)ureido)nicotinamide
US8992601B2 (en) 2009-05-20 2015-03-31 480 Biomedical, Inc. Medical implants
AU2010249558A1 (en) * 2009-05-20 2011-12-08 Arsenal Medical, Inc. Medical implant
US9265633B2 (en) 2009-05-20 2016-02-23 480 Biomedical, Inc. Drug-eluting medical implants
US20110319987A1 (en) 2009-05-20 2011-12-29 Arsenal Medical Medical implant
US8888840B2 (en) * 2009-05-20 2014-11-18 Boston Scientific Scimed, Inc. Drug eluting medical implant
US9309347B2 (en) 2009-05-20 2016-04-12 Biomedical, Inc. Bioresorbable thermoset polyester/urethane elastomers
US8372133B2 (en) * 2009-10-05 2013-02-12 480 Biomedical, Inc. Polymeric implant delivery system
SG191927A1 (en) 2011-01-14 2013-08-30 Vertex Pharma Solid forms of gyrase inhibitor (r)-1-ethyl-3-[6-fluoro-5-[2-(1-hydroxy-1-methyl-ethyl) pyrimidin-5-yl]-7-(tetrahydrofuran-2-yl)-1h-benzimidazol-2-yl]urea
KR101897952B1 (ko) 2011-01-14 2018-09-12 스페로 트리넴, 인코포레이티드 피리미딘 자이라제 및 토포이소머라제 ｉｖ 억제제
US9187953B2 (en) 2011-03-23 2015-11-17 Rytec Corporation Side column configuration for overhead roll-up door assemblies
ES2576298T3 (es) 2011-06-20 2016-07-06 Vertex Pharmaceuticals Incorporated Ésteres de fosfato de inhibidores de girasa y topoisomerasa
US9326951B2 (en) 2011-06-28 2016-05-03 Yale University Cell-free tissue engineered vascular grafts
WO2014015105A1 (en) 2012-07-18 2014-01-23 Vertex Pharmaceuticals Incorporated Solid forms of (r)-2-(5-(2-(3-ethylureido)-6-fluoro-7-(tetrahydrofuran-2-yl)-1h-benzo[d]imidazol-5-yl)pyrimidin-2-yl)propan-2-yl dihydrogen phosphate and salts thereof
EP3057953B1 (en) 2013-10-17 2018-08-15 Vertex Pharmaceuticals Incorporated Co-crystals of (s)-n-methyl-8-(1-((2'-methyl-[4,5'-bipyrimidin]-6-yl)amino)propan-2-yl)quinoline-4-carboxamide and deuterated derivatives thereof as dna-pk inhibitors
US11541149B2 (en) 2015-12-11 2023-01-03 Research Institute At Nationwide Children's Hospital Systems and methods for optimized patient specific tissue engineering vascular grafts
WO2018102074A1 (en) * 2016-11-04 2018-06-07 University Of Delaware Method for protecting skeletonized blood vessels

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4824436A (en) * 1985-04-09 1989-04-25 Harvey Wolinsky Method for the prevention of restenosis
US5171217A (en) * 1991-02-28 1992-12-15 Indiana University Foundation Method for delivery of smooth muscle cell inhibitors
US5521184A (en) * 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
US6306421B1 (en) * 1992-09-25 2001-10-23 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5354774A (en) * 1992-12-24 1994-10-11 Yale University Inhibition of smooth muscle cell proliferation by 8-methoxypsoralen photoactivated by visible light
US5279565A (en) * 1993-02-03 1994-01-18 Localmed, Inc. Intravascular treatment apparatus and method
US5788687A (en) * 1994-02-01 1998-08-04 Caphco, Inc Compositions and devices for controlled release of active ingredients
US5788979A (en) * 1994-07-22 1998-08-04 Inflow Dynamics Inc. Biodegradable coating with inhibitory properties for application to biocompatible materials
US6306165B1 (en) * 1996-09-13 2001-10-23 Meadox Medicals ePTFE small caliber vascular grafts with significant patency enhancement via a surface coating which contains covalently bonded heparin
US6245760B1 (en) * 1997-05-28 2001-06-12 Aventis Pharmaceuticals Products, Inc Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases
CO4940418A1 (es) * 1997-07-18 2000-07-24 Novartis Ag Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
CA2332314A1 (en) * 1998-06-11 1999-12-16 Cerus Corporation Use of alkylating compounds for inhibiting proliferation of arterial smooth muscle cells
WO2001060816A1 (en) * 2000-02-17 2001-08-23 Amgen Inc. Kinase inhibitors
WO2002045717A1 (en) * 2000-12-06 2002-06-13 Tularik Inc. Lometrexol combination therapy
US6872715B2 (en) * 2001-08-06 2005-03-29 Kosan Biosciences, Inc. Benzoquinone ansamycins

Also Published As

Publication number Publication date
JP2006519623A (ja) 2006-08-31
IL161583A0 (en) 2004-09-27
HUP0402036A3 (en) 2008-04-28
MXPA04003906A (es) 2005-02-17
HUP0402036A2 (hu) 2005-02-28
WO2003034938A2 (en) 2003-05-01
CO5580792A2 (es) 2005-11-30
PL374315A1 (en) 2005-10-03
ZA200403184B (en) 2005-05-12
BR0213497A (pt) 2006-05-23
US20040044405A1 (en) 2004-03-04
CN1635858A (zh) 2005-07-06
CA2464093A1 (en) 2003-05-01
EP1441749A2 (en) 2004-08-04
WO2003034938A3 (en) 2003-11-13
KR20040051618A (ko) 2004-06-18
RU2004116068A (ru) 2005-03-20
NZ532593A (en) 2007-11-30
NO20042133L (no) 2004-07-09
EP1441749A4 (en) 2010-05-19

Similar Documents

Publication Publication Date Title
ECSP045085A (es) Stent o injerto vascular recubierto con inhibidores de la proteína tirosina quinasa y método de usar el mismo
ATE265233T1 (de) Therapeutische inhibitoren der zellen der glatten gefässmuskulatur
Indolfi et al. Physical training increases eNOS vascular expression and activity and reduces restenosis after balloon angioplasty or arterial stenting in rats
ATE482725T1 (de) Auf stammzellen, vorläuferzellen oder targetzellen basierende behandlung von multiorganversagen.
ATE488195T1 (de) Endovaskuläre behandlung chronischer venöser insuffizienz
DE69626290D1 (de) Hemmung von gefässverengungen nach eingriffen an den gefässen
ATE478629T1 (de) Verbundene beinverlängerungen für eine endoluminal-prothese
Ramzy et al. Clinical applicability of preconditioning and postconditioning: The cardiothoracic surgeons's view
AR023391A1 (es) Composicion que contiene carnitina e inositol fosfato, util como suplemento dietario o droga
Thomas et al. Optimal conduit choice for open lower extremity bypass in chronic limb-threatening ischemia
DE60037032D1 (de) Anwendung von pdt zur inhibierung von hyperplasie der intima
Ishii et al. Enhanced hemostasis with a sealant consisting of Hydrofit and Surgicel
WO2002087472A8 (en) Stent-based delivery of statins to prevent restenosis
FR2811229B1 (fr) Utilisation d'un polysaccharide excrete par l'espece vibrio diabolicus en cicatrisation osseuse
Scaglioni et al. Versatility of perforator flaps for lower extremity defect coverage: Technical highlights and single center experience with 87 consecutive cases
DK0980251T3 (da) Vævsfaktor til påvirkning af blodkardannelse
DE29705218U1 (de) Teilmantel-Gefäßstütze zur medizinischen Behandlung von verengten Gefäßen, insbesondere Gefäßarealen mit Gefäßabzweig
RU2005103347A (ru) Способ замещения посттравматических дефектов тканей опорной поверхности стопы
GT200000180A (es) Cristales de inhibidor del intercambiador de sodio - hidrogeno.
Cooley Experimental vein graft research: a critical appraisal of mod-els
Eriksson Adrenergic nerve terminals in collateral arteries of the lower extremity
RU2004126789A (ru) Способ усиления артериального кровоснабжения колотрансплантата
UA3410U (uk) Спосіб ушивання кукси дванадцятипалої кишки при хірургічному лікуванні декомпенсованого постбульбарного стенозу
UA33813A (uk) Спосіб хірургічного лікування хворих з транспозицією магістральних судин серця
RU96111677A (ru) Способ хирургического лечения хронической венозной недостаточности